Evidence map›Paper›PMID 42204265›Full record

ArticleCommunications biology2026

SLFN5 restrains type I interferon responses and promotes glioblastoma via its N-terminal Schlafen core domain.

Ricardo E Perez, Kaitlyn E Kellar, Niyati Hansaria, Masha Kocherginsky, Mariafausta Fischietti, Frank Eckerdt, Leonidas C Platanias

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ricardo E PerezRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.ORCID 0000-0001-5912-3505
Kaitlyn E KellarRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Niyati HansariaRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Masha KocherginskyRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.ORCID 0000-0002-3510-9562
Mariafausta FischiettiRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Frank EckerdtRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. frank.eckerdt@northwestern.edu.ORCID 0000-0001-6853-850X
Leonidas C PlataniasRobert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA. l-platanias@northwestern.edu.ORCID 0000-0002-9740-7573

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
SLFN5: A Novel Therapeutic Target for GlioblastomaR01NS113352 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 2019 to 2023
$1.7M
CSRD VA I01 CX000916NCI NIH HHS P30 CA060553NINDS NIH HHS R01 NS113352U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) R01-NS113352U.S. Department of Veterans Affairs (Department of Veterans Affairs) I01-CX000916
6 · The paper itself

Abstract

Schlafen 5 (SLFN5) is an important regulator of Type I interferon (IFN-I) signaling and tumorigenesis, yet the structural basis for its biologic activity remains unclear. Here, we dissect functional domains of SLFN5 and uncover a key role for its N-terminal Schlafen core domain in IFN-stimulated gene (ISG) expression and glioblastoma proliferation, independently of the SWAVDL motif and the C-terminal Walker A/B motifs. Partial deletions within the core domain or substitution of two arginine residues (R271E/R326E) near the zinc finger motif disrupt chromatin association and phenocopy SLFN5 loss, including de-repression of ISGs that act as immune checkpoints, such as PD-L1 and PD-L2. In contrast, the C-terminal ATPase/helicase activity is dispensable for transcriptional repression and tumor-promoting functions. Structural comparison of human and mouse SLFN5 revealed a conserved architecture, and experimental evidence demonstrates that murine SLFN5 is a functional ortholog of human SLFN5. These findings establish SLFN5 as a key transcriptional modulator of malignant glioblastoma growth by dampening IFN-I responses and have implications for the development of future immunotherapy approaches.

Indexed as

Cell Cycle ProteinsGlioblastomaInterferon Type INuclear ProteinsAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceProtein DomainsSignal TransductionCell Cycle ProteinsInterferon Type INuclear ProteinsSLFN5 protein, human

Identifiers

PMID42204265
PMCPMC13493812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.